Search clinical trials for: IDP-122 Vehicle Lotion

Total 3205 results

Yongpeng Wang

Recruiting

A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Ovarian Cancer

China
Centre Leon Berard
GlaxoSmithKline

Recruiting

Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer (PARPi-PANC)

Metastatic Pancreatic Cancer

France
Haider Mahdi
Pfizer; Zenith Epigenetics

Recruiting

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
University of Chicago
AstraZeneca

Recruiting

Olaparib in Patients With HRD Malignant Mesothelioma

Mesothelioma | Homologous Recombination Deficiency

United States
Northwell Health
Tesaro, Inc.

Recruiting

Trial of Maintenance With Niraparib- Uterine Serous Carcinoma

Endometrial Cancer | Endometrial Carcinoma | Uterine Serous Carcinoma | Cancer of the Endometrium | Papillary Serous Endometrial Carcinoma

United States
Massachusetts General Hospital
Pfizer

Recruiting

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Breast Cancer

United States
AstraZeneca

Active, not recruiting

Phase I Comparative Bioavailability Study

Solid Tumors

Belgium, United Kingdom, Switzerland, Australia
North Eastern German Society of Gynaecological...
Clovis Oncology, Inc.; Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus...

Active, not recruiting

Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients (MAMOC)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer | Clear Cell Carcinoma

Germany
Shadia Jalal, MD
GlaxoSmithKline; Indiana University School of Medicine

Active, not recruiting

A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma

Adenocarcinoma | Gastric Cancer | Esophageal Cancer

United States
Pfizer

Completed

Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m

Breast Neoplasms | Metastatic Breast Cancer

United States
Pfizer

Active, not recruiting

A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

Neoplasms | Breast Neoplasms

Japan
Ospedale Policlinico San Martino
CRO "Centro Clinical Trials" IRCCS Ospedale Policlinico San Martino; Laboratory...

Withdrawn

Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy (Bohème)

Metastatic Colorectal Cancer
GlaxoSmithKline

Active, not recruiting

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease (ZEST)

Neoplasms, Breast

United States, Argentina, France, Netherlands, Finland, Spain, Israel, Poland, Romania, Mexico, Canada, Belgium, Germany, Hungary, Portugal, United Kingdom, Ireland, Australia, Italy, Brazil, Japan, Austria, Russian Federation, South... and more
AstraZeneca
British Columbia Cancer Agency

Completed

Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer

Breast Cancer | Ovarian Carcinoma

Canada
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Completed

Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell Carcinoma

Renal Cell Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Zai Lab (Shanghai) Co., Ltd.; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma. (CC-ANNIE)

Platinum-resistant Recurrent Clear Cell Ovarian Cancer

China
Spanish Oncology Genito-Urinary Group
AstraZeneca; Apices Soluciones S.L.

Completed

Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL) (IMANOL)

Prostate Cancer Metastatic

Spain
AstraZeneca

Completed

Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer (SOLI)

Breast Cancer | Ovarian Cancer

India
Chipscreen Biosciences, Ltd.

Completed

Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma

Non-hodgkin's Lymphoma

China
Samsung Medical Center

Completed

Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]

SCLC

Korea, Republic of
MedSIR
AstraZeneca; Experior

Completed

Preoperative Olaparib Endometrial Carcinoma Study (POLEN) (Polen)

Endometrial Carcinoma

Spain
Yale University

Withdrawn

Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC

Squamous Cell Carcinoma of the Head and Neck
AbbVie

Completed

A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors

Oncology | High Grade Serous Ovarian Cancer | BRCA Mutated | BRCA Mutated Breast Cancer
Roswell Park Cancer Institute
National Comprehensive Cancer Network

Active, not recruiting

Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage III Esophageal Adenocarcinoma AJCC v8 and other conditions

United States
Daiichi Sankyo, Inc.

Completed

AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment (DESIRABLE)

Rheumatoid Arthritis

Japan
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Terminated

A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer

China
VA Office of Research and Development

Completed

CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial (VAKCCT)

Skin Diseases | Carcinoma | Carcinoma, Squamous Cell | Carcinoma, Basal Cell | Neoplasms, Squamous Cell | Skin Neoplasms | Neoplasms, Basal Cell

United States
Korea University Anam Hospital
Takeda; Korean Cancer Study Group

Not yet recruiting

Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency

Efficacy
The University of Hong Kong

Recruiting

Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients

Endometrial Cancer

Hong Kong
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers (PALB2-PARPi-01)

Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers
Tianjin Huanhu Hospital

Recruiting

Niraparib Combined With Radiotherapy in rGBM

Recurrent Glioblastoma

China
Royal Marsden NHS Foundation Trust

Recruiting

Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR (MONITOR-UK)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United Kingdom
Institute of Cancer Research, United Kingdom
AstraZeneca; Cancer Research UK

Recruiting

ATr Inhibitor in Combination With Olaparib in Gynaecological Cancers With ARId1A Loss or no Loss (ATARI)

Gynaecological Cancers

United Kingdom
Mario Negri Institute for Pharmacological Research
North Eastern German Society of Gynaecological Oncology

Active, not recruiting

Newton Study (NEW Dosing mainTenance Therapy Ovarian caNcer) (Newton)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

Italy, Germany
Dana-Farber Cancer Institute
Tesaro, Inc.

Active, not recruiting

Niraparib in Patients With Pancreatic Cancer

Pancreatic Cancer

United States
Matthew Galsky
Icahn School of Medicine at Mount Sinai; AstraZeneca

Completed

Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

Metastatic Urothelial Cancer

United States
AstraZeneca

Completed

To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer (ORZORA)

BRCA or HRR+ Mutated Ovarian Cancer Patients

Italy, Spain, Canada, Czechia, Poland, United Kingdom, Hungary, Bulgaria
Pfizer

Terminated

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Early Breast Cancer

United States
UNICANCER
Clovis Oncology, Inc.; Fondation ARC

Completed

A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature (RUBY)

Metastatic Breast Cancer

France
AstraZeneca

No longer available

Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan

PSR Ovarian Cancer With a BRCA Mutation

Japan
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer (PIPSeN)

Non Small Cell Lung Cancer

France
Dana-Farber Cancer Institute

Withdrawn

Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
Journey Medical Corporation

Completed

Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis

Hyperhidrosis

United States
Taro Pharmaceuticals USA

Completed

Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris

Acne Vulgaris
Government Dental College and Research Institute...

Completed

1.2% Atorvastatin and 1.2% Simvastatin in Treatment of Chronic Periodontitis

Chronic Periodontitis
Sun Yat-sen University

Not yet recruiting

Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy (TASLARC)

Rectal Cancer

China
University of California, Irvine

Active, not recruiting

Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy

Colorectal Cancer | Metastatic Cancer | Colorectal Carcinoma | CRC

United States
Highlight Therapeutics
Merck Sharp & Dohme LLC

Active, not recruiting

BO-112 With Pembrolizumab in Unresectable Malignant Melanoma (SPOTLIGHT203)

Melanoma

Spain, France
Actelion

Completed

Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With Scleroderma (RAPIDS-2)

Systemic Sclerosis | Digital Ulcers

United States, Canada
Merrimack Pharmaceuticals
Sanofi

Completed

A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer

ER Positive, Her2 Negative Breast Cancer Patients | Triple Negative Breast Cancer Patients

United States

Search clinical trials for: IDP-122 Vehicle Lotion

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations